Analyzing BioLife Solutions (BLFS) and Zynex Inc. common stock (ZYXI)

BioLife Solutions (NASDAQ: BLFS) and Zynex Inc. common stock (OTCMKTS:ZYXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.


This table compares BioLife Solutions and Zynex Inc. common stock’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLife Solutions -13.17% -18.99% -15.72%
Zynex Inc. common stock 33.24% 356.96% 128.90%

Institutional and Insider Ownership

11.9% of BioLife Solutions shares are owned by institutional investors. Comparatively, 0.0% of Zynex Inc. common stock shares are owned by institutional investors. 38.5% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BioLife Solutions and Zynex Inc. common stock’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLife Solutions $11.02 million 15.23 -$2.51 million ($0.21) -56.48
Zynex Inc. common stock $23.43 million 4.81 $7.36 million $0.22 15.45

Zynex Inc. common stock has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Zynex Inc. common stock, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLife Solutions and Zynex Inc. common stock, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions 0 0 4 0 3.00
Zynex Inc. common stock 0 1 0 0 2.00

BioLife Solutions presently has a consensus target price of $10.33, indicating a potential downside of 12.87%. Given BioLife Solutions’ stronger consensus rating and higher possible upside, equities research analysts clearly believe BioLife Solutions is more favorable than Zynex Inc. common stock.

Risk & Volatility

BioLife Solutions has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Zynex Inc. common stock has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.


Zynex Inc. common stock beats BioLife Solutions on 8 of the 14 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

About Zynex Inc. common stock

Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with's FREE daily email newsletter.

Leave a Reply